## Special Issue

## Recent Advances in Parkinson's Disease

## Message from the Guest Editor

Parkinson's disease is the second most common neurodegenerative disease in the world and affects millions of people globally. Much is left to discover about this disease. There is no resolutive treatment; the cause is unknown; diagnostic tools are scanty; and, so far, it remains essentially a clinical diagnosis. However, in the recent decades several treatments have been available that alleviate signs and symptoms. Pathogenesis as well as some genetic aspects have been partially clarified and linked to clinical pictures. Magnetic Resonance is being used to study brain modification related to the disease. Other diagnostic tools are being developed, and we are about to reach the goal of personalized medicine applied to Parkinson's disease. We need to assess our current position in order to move forward.

#### **Guest Editor**

Dr. Mario Rango

Department of Neurological Sciencies and Mental Health, University of Milano, Fondazione Ca' Granda, IRCCS, Ospedale Maggiore Policlinico, Milan, Italy

### Deadline for manuscript submissions

closed (30 June 2022)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/85710

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



## About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

#### **Editor-in-Chief**

#### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

## **Journal Rank:**

CiteScore - Q1 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

